Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
about
Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestationsThe potential utility of B cell-directed biologic therapy in autoimmune diseases.Advances in the use of biologic agents for the treatment of systemic vasculitisSuccessful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab.Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Biological therapies: new treatment options for ANCA-associated vasculitis?ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.Current state of biologicals in the management of systemic vasculitis.Widespread cranial nerve palsies while on cyclophosphamide therapy: a very rare manifestation of Wegener's granulomatosis (granulomatosis with polyangitis).Hematopoietic stem cell transplantation (HSCT) for primary systemic vasculitis and related diseases.Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisRecommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.Wegener's granulomatosis of the orbit: a review of clinical features and updates in diagnosis and treatment.New indications for biological therapies.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.Experience with low-dose rituximab in off-label indications at two tertiary hospitals.Impact of rituximab trials on the treatment of ANCA-associated vasculitis.Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.B cell depletion: rituximab in glomerular disease and transplantationEfficacy and safety of rituximab in rheumatic diseases.Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: A case report and literature review.Indications of rituximab in autoimmune diseases.Make the grade for Wegener's granulomatosis after kidney transplantation.Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.A child with Wegener's granulomatosis and severe hemophilia A: interplay of disease processes.Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
P2860
Q26748200-D2FC8649-3F32-4E1A-A39F-F56121D48385Q33377109-216D456D-57ED-4128-8E37-ECB49B7E1E2BQ34065598-46D9681B-EB39-4B0C-AB49-8EEDFF1E70A7Q34244998-182B4D7E-21B3-4A8D-A4AE-328CE8482988Q34377832-9D0C291A-9A26-4154-B49E-3FAAEF8F2EA0Q35557832-08225FEF-C470-4258-B4AE-CCB6062DED46Q36152477-49D4BE36-FF82-42BB-9D2F-8CCCD01D3F1BQ36171750-5E85D042-F16D-4F7A-8C9F-ACC64E2FD990Q36504479-55AA45F5-9740-42F8-B0CD-AF17BDF48DDDQ36684589-18C4E562-09B8-4CC8-8D23-30DA30E69D88Q36764935-4EA4E4C9-036E-437E-A7B3-4CB7CBC353DEQ36802625-3C3CB9A2-50C2-4620-8607-46FCD90F868AQ36958331-22A80559-4FC7-4E2C-B505-EBA63282D86EQ37292930-484DC073-A138-46DA-B57F-EF7A37717DB4Q37311093-505B7C7C-51D5-4EB6-887B-1AD69FA23D86Q37546823-C3A04129-76D4-4DAC-9808-CC4A25B77F69Q37640836-6E182AD4-F1B0-49FA-AC0D-C60C3C80E32FQ37879814-48667B36-E6E7-4129-8B5F-84F1AAE56B1EQ37940606-A73606EE-3241-4090-89BF-DB91BA8BD056Q37947157-61A141C9-C610-49C9-996C-CBD3A91D0EE9Q38057370-EA11DA16-8D77-4869-9C79-6417C1CF6F3CQ38126924-2774C192-937F-445F-8CE9-664A5E2E52ECQ38152651-6B4D5C03-19E4-42FA-8143-06DD1C782DB8Q38155087-EE284B06-2A29-48F3-B067-5A3886D6912DQ38189360-29A15D77-438F-4763-8A3A-0A3F7A227B13Q38353577-7214FD33-D185-4DDD-A3E3-AF748636DED8Q38367357-C0292BC6-8433-470E-91B9-39EAF460E7CBQ39925216-640AFE56-9488-4E2D-A5FC-6B4B3BF5A850Q40320143-34F37B29-4516-44DF-944C-4533299A7205Q42239031-527E5FB6-20F3-4B5F-B608-D20394F81F1BQ45865191-1085E844-7084-42A7-823D-7A1A0A0AADA1Q48113733-38A03372-2EBD-448D-9E10-F61E441E3B2AQ48592090-909184F4-BF42-4CF4-B4C5-795D68CCA123
P2860
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lack of efficacy of rituximab ...... y granulomatous manifestations
@ast
Lack of efficacy of rituximab ...... y granulomatous manifestations
@en
type
label
Lack of efficacy of rituximab ...... y granulomatous manifestations
@ast
Lack of efficacy of rituximab ...... y granulomatous manifestations
@en
prefLabel
Lack of efficacy of rituximab ...... y granulomatous manifestations
@ast
Lack of efficacy of rituximab ...... y granulomatous manifestations
@en
P2093
P2860
P356
P1476
Lack of efficacy of rituximab ...... y granulomatous manifestations
@en
P2093
B Hellmich
J Voswinkel
K Holl-Ulrich
P Lamprecht
P2860
P304
P356
10.1136/ARD.2005.044420
P407
P577
2005-11-03T00:00:00Z